NONOF 164.70 Stock Price Novo Nordisk A/S
Range: | 94.36-149.55 | Vol Avg: | 34901 | Last Div: | 1.45 | Changes: | -3 |
Beta: | 0.17 | Cap: | 450.09B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Fri May 07 2010 | Empoloyees: | 71880 |
CUSIP: | | CIK: | 0000353278 | ISIN: | DK0062498333 | Country: | DK |
CEO: | Mr. Lars Fruergaard Jorgensen | Website: | https://www.novonordisk.com |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.